Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia
暂无分享,去创建一个
H. Kantarjian | G. Garcia-Manero | Xuelin Huang | T. Kadia | F. Ravandi | E. Jabbour | C. Dinardo | R. Kanagal-Shamanna | S. O'brien | J. Burger | J. Khoury | N. Jain | N. Short | J. Jorgensen | A. Ferrajoli | B. Dabaja | P. Kebriaei | I. Khouri | Y. Alvarado | M. Ohanian | K. Sasaki | G. Montalban-Bravo | S. Paul | M. Yilmaz | N. Daver | Jovitta Jacob | Meagan Rostykus | R. Garris | J. Jacob | Rebecca E. Garris | Shilpa Paul | Naval Daver | Naval G Daver
[1] H. Kantarjian,et al. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin , 2020, British journal of haematology.
[2] M. Loh,et al. Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): Results from central CD22 testing on the Children’s Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL). , 2020 .
[3] H. Kantarjian,et al. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database , 2020, Leukemia & lymphoma.
[4] H. Kantarjian,et al. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management , 2019, Cancer.
[5] D. Leongamornlert,et al. Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14 , 2019, Blood.
[6] Jiqiang Yao,et al. Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) , 2019, Blood.
[7] P. Vyas,et al. The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results , 2019, Blood.
[8] H. Kantarjian,et al. Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories , 2019, Blood.
[9] Jeremy M. Stewart,et al. A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia , 2019, Blood.
[10] M. Konopleva,et al. Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement , 2019, Blood.
[11] M. Konopleva,et al. Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis , 2019, Cancer.
[12] H. Dombret,et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia , 2019, Leukemia & lymphoma.
[13] M. Liedtke,et al. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin , 2019, American journal of hematology.
[14] K. Davis,et al. Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia. , 2019, Cancer research.
[15] A. Logan,et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts , 2018, American journal of hematology.
[16] M. Konopleva,et al. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage , 2018, Cancer.
[17] C. Pui,et al. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia , 2018, JAMA oncology.
[18] M. Konopleva,et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. , 2018, The Lancet. Oncology.
[19] Mithat Gonen,et al. Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[20] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[21] H. Kantarjian,et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. , 2017, The Lancet. Haematology.
[22] W. Klapper,et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia , 2017, The New England journal of medicine.
[23] M. Konopleva,et al. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual disease , 2017, Cancer.
[24] R. Hills,et al. Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia , 2016, Leukemia.
[25] Giovanni Martinelli,et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia , 2016, Haematologica.
[26] M. Liedtke,et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.
[27] H. Dombret,et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. , 2016, Blood.
[28] Xuelin Huang,et al. Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia , 2016, British journal of haematology.
[29] M. Konopleva,et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. , 2015, The Lancet. Oncology.
[30] H. Kantarjian,et al. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody , 2015, American journal of hematology.
[31] H. Kantarjian,et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia , 2013, Cancer.
[32] Robert Huether,et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia , 2013, Nature Genetics.
[33] Carsten Denkert,et al. Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization , 2012, PloS one.
[34] H. Kantarjian,et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet Oncology.
[35] M. Tallman,et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.
[36] Rajesh Chopra,et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.
[37] H. Kantarjian,et al. Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia , 2004, Cancer.